Login / Signup

Measurable Residual Disease Before Reduced-Intensity Allogeneic Transplantation in Patients With Myeloid Malignancy.

Gege GuiLaura W DillonChristopher S Hourigan
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Keyphrases
  • bone marrow
  • stem cell transplantation
  • high intensity
  • dendritic cells
  • hematopoietic stem cell
  • acute myeloid leukemia
  • mesenchymal stem cells
  • high dose
  • cell therapy
  • immune response
  • low dose